Olanzapine Milpharm

Olanzapine, the active ingredient in Olanzapine Milpharm, is an atypical antipsychotic presented as a tablet for oral use. It treats schizophrenia and bipolar disorder in adults, helping to control psychotic symptoms and stabilize mood. Olanzapine works by modulating dopamine and serotonin activity in the brain, which contributes to its therapeutic effects in a range of psychiatric conditions.

GNH USA supplies Olanzapine Milpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olanzapine is an atypical antipsychotic that modulates dopamine and serotonin pathways in psychiatric disorders.

Schizophrenia: reduces positive and negative psychotic symptoms and improves overall functioning. Bipolar disorder (manic episodes): stabilises mood and prevents recurrence of manic symptoms. Schizoaffective disorder: alleviates both psychotic and mood components of the illness.

Olanzapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Weight gain: increased appetite leading to gradual weight increase. - Sedation: drowsiness or feeling unusually tired. - Dry mouth: reduced salivation causing discomfort. - Constipation: slowed gastrointestinal motility.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever and muscle rigidity. - Agranulocytosis: severe drop in white blood cells. - Tardive dyskinesia: involuntary movements after prolonged use. - Severe hyperglycemia: marked increase in blood glucose levels. - Myocarditis: inflammation of the heart muscle.

When prescribing Olanzapine, clinicians should consider several safety measures.

Monitor metabolic parameters: regularly check weight, fasting glucose, and lipid profile. Assess extrapyramidal symptoms: watch for tremor, rigidity, or abnormal movements. Evaluate cardiovascular status: be aware of orthostatic hypotension and possible QT prolongation. Review hepatic function: dose adjustment may be required in liver impairment. Store at ambient temperature: keep in the original container, protect from moisture and light.

Olanzapine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP1A2 inhibitors (e.g., fluvoxamine): may increase olanzapine plasma levels. - Carbamazepine: enzyme induction can reduce olanzapine exposure. - Concurrent antipsychotics: additive risk of QT prolongation and sedation.

Moderate Interactions (Monitor Closely): - Antihypertensives: additive hypotensive effect may occur. - Anticholinergic agents: increased anticholinergic burden can worsen side effects. - Glucose‑lowering drugs: risk of hyperglycemia may be heightened.